Another retrospective study by Jukić et al. (2018) showed that CYP2C19 PM (n = 88; 4%) and UM patients (n = 604; 28%) were more likely to switch from escitalopram to another AD compared with NM patients (n= 837; 39%) [20]. This evidence concerns the gene CYP2C19 and Alzheimer disease.